Check-Cap claims BMO’s Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime

Core Viewpoint - Check-Cap Ltd. publicly condemns MediPharm Labs and its Chairman Chris Taves for spreading false and defamatory statements aimed at harming Check-Cap's reputation during a sensitive time for Israeli companies [1][2][5]. Group 1: Allegations and Responses - Check-Cap is disturbed by Taves' actions, which are seen as exploiting wartime circumstances to spread false information that could negatively impact Check-Cap's reputation and stock price [2][5]. - MediPharm Labs' May 23, 2025 press release included statements from Taves that Check-Cap believes to be false, particularly regarding alleged deficiencies in Check-Cap's public disclosures [3][4]. - Check-Cap accuses Taves of misusing his position to manipulate Check-Cap's stock price, violating U.S. securities laws [4]. Group 2: Company Background - Check-Cap is a clinical-stage medical diagnostics company focused on colorectal cancer screening through its investigational device, C-Scan, which is not yet available for sale in the U.S. [6].